直 Japanese PDF Font
  • 弁護士等
  • 業務内容
  • 論文等
  • オフィス
  • 事務所概要
  • 採用情報
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • 実績

知財ポートフォリオ管理

About

取り巻く環境をよく精査して好機を捉える

イノベーションを創出する新興企業、多国籍企業、及びその他の知的財産を扱う組織は、IP戦略のオプションに直面した際、弊所に助言を仰ぎます。弊所はクライアントの商業部、法務部、及び技術部のスタッフと協力して、クライアントの掲げるビジネス目標に沿ったIPポートフォリオを構築します。欧州、英国、米国の拠点を通じて、現存又は作成中のポートフォリオを精査する際には、侵害を回避でき強いIP保護のある製品に基づきビジネスプランが形成されていることを見極めます。これには、技術をライセンス供与又は重要でない資産を売却して収入源とする、コスト削減のために資産を寄付又は放棄する、及び現存するポートフォリオを強化かつ拡大するための買収の提案をする、ことにより資産の特定や優先順位付けをしていく作業が伴います。

Everyone in this practice

実績

Comprehensive patent transactions and strategic counseling for one of the largest pharmaceutical companies in the world

Finnegan is lead and preferred IP transactions counsel for one of the largest pharmaceutical companies in the world, handling more than 50 diligence projects each year, including all IP and related transactional aspects of the matters. The transactions span the full gamut of technologies from small molecule through biologics such as antibodies, oligonucleotides, and gene therapies. Finnegan also provides extensive assistance with post-deal integration procedures and subsequent global prosecution and portfolio strategy, ensuring a seamless transition of IP assets to the company and maximum value from acquired IP.

Global prosecution and portfolio management for major pharmaceutical company

Finnegan is lead and preferred IP strategy counsel for one of the largest pharmaceutical companies in the world, handling all aspects of prosecution and portfolio management for multiple top-tier products for the client.  The work spans the gamut from drafting and prosecution through larger strategic planning, patent term extension, and pre-litigation preparation on blockbuster small molecule and biologic products in the oncology, rheumatology, immunology, neuromuscular, and cell and gene therapy spaces.

Utility and design patent applications for brain machine interface company

Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.

Helping a pioneer company navigate cases through the USPTO

Guiding a multinational technology company through U.S. Patent and Trademark Office (USPTO) proceedings involving semiconductor manufacturing, image processing, and artificial intelligence (AI) technologies by leveraging advanced drafting and prosecution strategies to align with and support its business goals.

Strategic patent support led to startup acquisition

Advised a cycling-focused startup on the preparation and prosecution of a foundational patent application, which played a key role in its acquisition by a global leader in GPS-enabled technology across fitness, outdoor, marine, automotive, and aviation markets.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement
Finnegan designed and prosecuted a global patent strategy with client Eisai on MORAb-202, an antibody-drug conjugate (ADC), providing pivotal support for Eisai’s exclusive, global strategic collaboration agreement with Bristol-Myers Squibb Company (BMS) to co-develop and co-commercialize the asset. Under the publicly announced financial terms of the agreement, BMS will pay Eisai $650 million, including $200 million as payment towards Eisai’s research and development expenses. Eisai is also entitled to receive up to $2.45 billion in potential future development, regulatory, and commercial milestones.

More

Insights

Conference

Singapore IP Week 2026

August 26-27, 2026

Seminar

IAM and WTR Live: Australasia IP Forum 2026

August 11, 2026

Melbourne

Conference

Sustainable Fuels Global Summit

March 11-12, 2026

Rotterdam

Webinar

Managing Risk in Franchising: Data Privacy and Brand Protection Best Practices

November 20, 2025

Webinar

Webinar

Patent Term at Risk? Navigating OTDP’s Impact on PTA, PTE, and Reissue in Light of Recent Federal Circuit Decisions

November 20, 2025

Webinar

Conference

IAM and WTR Live: Latin America IP Summit 2025

November 4-5, 2025

Sao Paulo

More

Upcoming Events

Conference

Singapore IP Week 2026

August 26-27, 2026

最新情報

Award/Ranking

31 Finnegan Attorneys Recognized by Best Lawyers 2027

August 20, 2026

Award/Ranking

Fourteen Finnegan Attorneys Named to the 2026 IAM Strategy 300 List

August 13, 2026

Award/Ranking

Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards

August 10, 2026

Commentary

Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects

June 30, 2026

Commentary

Israel’s Next Big Bet: The Innovations Redefining Startup Nation in 2026

December 3, 2025

Award/Ranking

Finnegan Partner Adriana Burgy Named a 2025 BTI Client Service All-Star

August 21, 2025

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • プライバシー
  • 免責事項
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP